NEW YORK, June 3, 2026, 15:07 EDT
Phibro Animal Health Corp shares climbed over 10% on Wednesday after a director bought shares on the open market in the wake of a recent drop. The move put the stock ahead of the wider market.
Phibro shares jumped 10.3% to $31.45 on the Nasdaq during afternoon trading. The stock earlier reached $31.67. Latest data put the company’s market value at around $1.29 billion.
Phibro is looking for stability after selling off in May. Despite a bounce on Wednesday, shares are still trading far under the 52-week high at $60.08. Investors don’t seem convinced yet, with worries sticking about Brazil regulation and questions on how long the company can keep up its improved guidance.
Director E. Thomas Corcoran picked up 10,000 Class A shares on May 29 at a weighted average price of $31.77, according to a Form 4. The weighted average is figured across trades and adjusted for size. After the buy, Corcoran owned 41,459 shares, including 1,459 from a dividend reinvestment plan.
Phibro shares moved near the dividend record date. The company set a 12 cent per share quarterly cash dividend, with payment scheduled for June 24. Shareholders on record at the close of June 3 will get the dividend.
The rally was more pronounced than moves in other stocks and indexes. Zoetis climbed 0.9%, Elanco was up 3.1%, and IDEXX gained 1.4%. The SPDR S&P 500 ETF, which tracks the wider market, dropped 0.5%. The small-cap iShares Russell 2000 ETF fell 1.4%.
Phibro’s latest quarter gave bulls fresh ammo. Net sales hit $383.5 million, rising 10%. Adjusted EBITDA came in at $60.8 million, up 11%. CEO Jack Bendheim credited the gains to “continued strength” in the Animal Health division, pointing to demand for medicated feed additives, nutritional specialties, and vaccines. Phibro Animal Health Corporation
The company bumped up the bottom of some fiscal 2026 guidance ranges last month. It put out a net sales forecast of $1.46 billion to $1.50 billion and sees adjusted diluted EPS between $2.98 and $3.10.
Brazil could be a problem. MAPA, the country’s agriculture ministry, put out new rules in April that ban the import, manufacture, sale and use of some antibiotic feed growth promoters—like virginiamycin and bacitracin—following a 180-day grace period. After that, producers will need a vet’s prescription to use them. Phibro is guiding for only a small impact in fiscal 2026, but said the hit could be worse if prescription demand falls short or regulatory approvals lag.
Recent notes from the sell side have been cautious. MarketBeat’s roundup put the consensus at Hold, with a $38.80 target price, and flagged Citi’s downgrade to neutral with a $44 target. Zacks also shifted the stock to Hold.
Wednesday’s trading rebound appears to be driven by insider buying rather than a new forecast from the company. The next thing to watch is if buyers hold their position after the dividend date and once the market reacts further to Brazil’s prescription change.
